Sustained Response to Low-Dose Imatinib Mesylate in a Patient with Chronic Myelomonocytic Leukemia with t(5;12)(q33;p13)

Publisher： Karger

E-ISSN： 1421-9662|119|1|57-59

ISSN： 0001-5792

Source： Acta Haematologica, Vol.119, Iss.1, 2008-02, pp. : 57-59

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Case of Chronic Myelomonocytic Leukemia with Severe Eosinophilia Having t(5;12)(q31;p13) with t(1;7)(q10;p10)

By  

Acta Haematologica, Vol. 114, Iss. 2, 2005-08 ,pp. : 104-107

Karger

Access to resources Recommend Favorite

Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 3, 2015-03 ,pp. : 338-339

John Wiley & Sons Inc

Access to resources Recommend Favorite

Leukemia cutis in a patient with chronic myelomonocytic leukemia

By  

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Vol. 16, Iss. 1, 2018-01 ,pp. : 81-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Imatinib Mesylate Resistance in a Chronic Myeloid Leukemia Patient with a Novel e8a2 BCR-ABL Transcript Variant

By  

Acta Haematologica, Vol. 120, Iss. 3, 2008-11 ,pp. : 146-149

Karger

Access to resources Recommend Favorite

Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia

By  

Acta Haematologica, Vol. 127, Iss. 4, 2012-04 ,pp. : 228-234

Karger

Access to resources Recommend Favorite